We have also shown that FTY720, an immunosuppressive agent recently approved by the FDA for the treatment of relapsed multiple sclerosis [41], has significant in vitro activity in MCL, promoting MCL cell death through caspase-independent ROS generation and down-modulation of p-Akt and Cyclin D1, with subsequent accumulation of cells in G0/G1 and G2/M phases of the cell cycle [42]. The gene discussed is AKT1; the disease is mantle cell lymphoma.